

Ripple Science and Velocity Research Sign Pilot Agreement for Ripple Recruit Software

Ripple Recruit will deploy at leading Velocity Research sites as part of a digital transformation strategy targeting recruitment and retention best practices.

ANN ARBOR, MI, UNITED STATES, April 19, 2022 /EINPresswire.com/ -- Ripple Science, a digital clinical trial software company, today announced a partnership with Velocity Clinical

Research to deploy Ripple Recruit on Ripples new enterprise software platform, providing Velocity's patient recruiting teams access to a complete set of direct-to-patient tools that give an exceptional patient experience from first contact through to consent.



“

We must effectively recruit more people to trials, which is why we partner with leading technology providers like Ripple Science to help us realize our goals.”

Dr Paul Evans, CEO of Velocity Clinical Research

Ripple Recruit is the world's only direct-to-patient software platform designed to support decentralized (DCT), virtual, and hybrid clinical trial workflows. Designed and audited to 21 CFR Part 11, HIPAA, GDPR and SOC2 standards, Ripple Enterprise enables patient navigators to spend more time with better information as they nurture each patient through the recruitment phase of the patient journey, creating a better patient experience while driving down costs and expanding access to a more diverse pool of patients.

“We are excited to partner with Velocity Clinical Research which is a leader in the industry,” said Peter Falzon, CEO of Ripple Science. “Velocity puts patient care at the center of everything they do and has the ability to leverage data and insights from Ripple to operationalize recruiting best practices at scale.”

Velocity Clinical Research's CEO, Dr Paul Evans, said: “Velocity's mission is to speed up clinical research so that life-saving drugs can get to market quicker. To do this, we must effectively recruit more people to trials, which is why we partner with leading technology providers like Ripple Science to help us realize our goals.”

About Ripple Science:

Ripple Science, a clinical trial technology company, is leading the digital transformation in clinical trials with a direct-to-patient software platform that was built by researchers for researchers. By improved the user experience, increasing regulatory compliance, and further connecting the ecosystem through digital innovation and technology, Ripple delivers real-time transparency, game-changing efficiencies, and more secure workflows and data sharing concerning all aspects of patient engagement from first contact to last patient visit, whether virtual or in-person

Ripple Science was named a [Top 50 Company to Watch in 2021](#) by Michigan Celebrates Small Businesses and recognized in 2022 by Purpose Jobs and Cronicle Tech News as one of the [fastest growing health tech startup companies in Ann Arbor](#).

About Velocity Clinical Research:

Velocity Clinical Research, headquartered in Durham, NC, is the leading integrated site organization for clinical trials, offering dedicated site capabilities to help biopharmaceutical and contract research organization customers find the right patients for their studies. Velocity supports global drug development in primarily conducting phase II and phase III clinical trials. The company has 30 U.S. locations across 14 states.

We place the care of the patient at the heart of everything we do. With over 35 years of experience running sites and more than 7,000 studies completed, Velocity has refined its patient recruitment strategies while maintaining a focus on delivering timely and reliable data quality. For more information visit our website at <https://velocityclinical.com>.

Anna Falzon
Ripple Science
anna@ripplescience.com

This press release can be viewed online at: <https://www.einpresswire.com/article/568760543>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.